Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage
Primary Purpose
Postpartum Hemorrhage
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Misoprostol
Oxytocin
Sponsored by
About this trial
This is an interventional prevention trial for Postpartum Hemorrhage
Eligibility Criteria
Inclusion Criteria:
- pregnant women
- term pregnancy
- singleton pregnancies
- booked for elective cesarean section
Exclusion Criteria:
• Medical disorders involving the heart,liver,kidney or brain
- Diabetes mellitus and hypertension
- Blood disorders (e.g. coagulopathies , thrombocytopenia )
- Patients requiring blood transfusion due to anemia
- Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies
- Placenta previa or placental abruption
- Previous major obstetric haemorrhage (>1000ml)in previous deliveries
- Known fibroid or adenomyosis
- Severe preeclampsia
- Uterine anomalies
- Women who received anticoagulant therapy
Sites / Locations
- Assiut Faculty of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
study group
control group
Arm Description
patients will receive buccal misoprostol
patients will receive intravenous oxytocin
Outcomes
Primary Outcome Measures
mean blood loss
the amount of blood in towels and suction drain
Secondary Outcome Measures
Full Information
NCT ID
NCT03676621
First Posted
September 17, 2018
Last Updated
September 23, 2021
Sponsor
Assiut University
1. Study Identification
Unique Protocol Identification Number
NCT03676621
Brief Title
Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage
Official Title
Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage :a Randomized Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
August 30, 2021 (Actual)
Study Completion Date
September 20, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy
Detailed Description
patients and methods:
Type of Study
A prospective registered, double blinded, randomized controlled trial
Settings and localizations:
Operative list and emergency unit at Obstetrics and Gynecology Department, Women Health Hospital, Assiut university, Egypt
Preliminary assessment of the patient
Obtain a detailed history from the patient
Examination of the patient
General examination and evaluation of the vital signs ofthe patient ( pulse , blood pressure , temperature and respiratory rate)
Obstetrical examination
Ultrasonograghic assessment (fetal viability , number of gestation, placental location, amniotic fluid index)
Investigations ( complete blood count, Prothrombin time and concentration).
Inclusion criteria:
All legally adult pregnant women , above 18 years old ,at term with singleton pregnancies booked for elective caesarean section accepting to participate in the study.
Indications of cesarean section:
Repeated caesarean section(previous 2 cs or more).
previous one caesarean with oligohydramnios.
previous one caesarean with contracted pelvis.
previous one caesarean with malpresentation.
previous one caesarean section with decreased fetal movement.
primigravida with malpresentation.
primigravida with contracted pelvis.
Exclusion criteria:
Medical disorders involving the heart,liver,kidney or brain.
Diabetes mellitus and hypertension.
Patients requiring blood transfusion due to anemia.
Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies.
Placenta previa or placental abruption.
Previous major obstetric haemorrhage (>1000ml in previous Deliveries).
Known fibroid or adenomyosis.
Severe preeclampsia.
Uterine anomalies.
Women who received anticoagulant therapy.
Blood disorders (e.g. coagulopathies , thrombocytopenia).
Consent
Verbal and written consent were obtained from all eligible women .
The candidate women were divided into two groups. A computer generated random numerical table was used by an independent statistician to prepare sealed opaque envelopes containing a group assignment. Two groups of envelopes, corresponding to two study groups, were given to a third party (a nurse), who was unaware of the contents. The nurse distributed envelopes to patients, alternating between the groups. Patientsassigned to group 1 received 5 IU oxytocin IV after delivery of the fetus+ 2 tabs placepo . Patients assigned to group 2 received 400 in the buccal space after anaesthesia + Iv saline infusion
Procedure:
Cesarean deliveries were performed by well- trained resident doctor supervised by Assistant lecturer or Obstetrician consultant.
Cesarean section was performed under spinal anesthesia. Novasoconstrictor was used unless the blood pressure dropped by 20% fromthe baseline value; if this was the case, 10 mg ephedrine was given.
Cesarean Delivery technique was the same in all recruited women.
Abdominal skin incision was done through a Pfannenstiel incision 2 to 3cm above the symphysis pubis, with the mid portion of the incision within the shaved area of the pubic hair for a length of about 10-12cm was done. After the rectus fascia was opened, the rectus
muscles were separated and dissected off the peritoneum which was
picked up between two tissue forceps and opened longitudinally. The visceral peritoneum was dissected sharply and gently to separate the bladder from the uterus. The
uterus was opened through a transverse lower segment incision.
After clamping of the umbilical cord, the women received 1.5 gm Ampicillin -Sulbactam (Ultracillin, Sedico, Egypt) and 80 mg garamycin (Epigent, EPICO, EGYPT)
Uterine repair by absorbable continuous vicryl 1 sutures in two layers , parietal peritoneum was sutured by absorbable continuous vicryl sutures, rectus sheath was closed by absorbable continuous vicryl 1.
subcutaneous fatty layer was closed by absorbable continuous vicryl 0sutures, skin was closed by vicryl 2-0 by subcuticular sutures.
All the towels were weighed before and after cesarean section and the difference were calculated, the amount of intraoperative blood loss was estimated in the suction apparatus in ml. A trained nurse was responsible for blood and amniotic fluid collection during surgery using two separate suction sets, as well as for weighing the surgical towels before and after surgery; all towels that were used were of the same size and weight and every 1 gm increase in weight was equated with 1-mLblood loss. The total amount of intra-operative blood loss was calculated.(blood loss in suction apparatus plus weight difference of used towels
Second trained nurse was responsible for post-operative external blood loss measurement during the first 24 hours after surgery by weighing the soaked towels placed in the vulvar area. The post-operative blood loss was calculated (weight difference of towels placed in the vulvar area .The overall blood loss was calculated. Another blood picture was obtained 24 hours postoperative to detect changes in Hb level. The same nurse was responsible for follow up body temperature 2 hours after caesarean section (feverish if temperature is 38ºC or greater) and observation of the patient for nausea , vomiting , chills and diarrhea.
Outcomes:
Primary outcomes: involved estimation of intraoperative and
postoperative blood loss for 24 hours ( blood loss estimation started immediately following the skin incision)
Secondary outcomes:
Changes in hemoglobin concentration ( hemoglobin concentrations were measured 2 hours before surgery and 24 hours after surgery)
Misoprostol-induced maternal adverse effects (postoperativenausea, vomiting, diarrhea, fever and chills .
Need to use other uterotonic drugs (oxytocin or ergometrine).Need to do further surgical interventions ( uterine artery ligation ,hysterectomy or re-exploration of the patient)
Need for blood transfusion.
Sample Size:
Sample size was calculated based on the primary outcome (the amount of intraoperative blood loss during cs ) based on the results of previous study ,the mean blood loss with the use of Iv oxytocinas588.9ml with a standerd deviation of 96.3 ml (10).
Assuming that buccal misoprostol is more effective in reducing blood loss by 10% 77 participants in each group will have 95% power at significance to detect such a 5% difference
women were include in each group taking in account a 10% 77 drop-out rate (Epi-info: centers for disease control and prevention
Atlanta, GA)
Approval of Ethical Considerations:
The Research Ethics Committee of Faculty of Medicine, Assiut
University approved the study protocol. Pregnant women who would
undergo elective lower segment cesarean section at term ( ≥ 37 weeks)
with normal fetal heart tracing received written and verbal information
about the study and were asked to participate. Those who agreed signed
an informed consent form
Statistical Analysis:
Data entry and analysis were carried out using Statistical Package
of Social Sciences for windows (SPSS, Chicago, Illinois, USA) version 20
Quantitative variables were presented in terms of mean± standard
deviation and qualitative variables were expressed as frequency and
percentage. Tests of significance (T-test and chi-square) were calculated
Significance level was set at P value < 0.05.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
154 (Actual)
8. Arms, Groups, and Interventions
Arm Title
study group
Arm Type
Experimental
Arm Description
patients will receive buccal misoprostol
Arm Title
control group
Arm Type
Active Comparator
Arm Description
patients will receive intravenous oxytocin
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
buccal tablets
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Intervention Description
intravenous drip
Primary Outcome Measure Information:
Title
mean blood loss
Description
the amount of blood in towels and suction drain
Time Frame
1 hour
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
pregnant women
term pregnancy
singleton pregnancies
booked for elective cesarean section
Exclusion Criteria:
• Medical disorders involving the heart,liver,kidney or brain
Diabetes mellitus and hypertension
Blood disorders (e.g. coagulopathies , thrombocytopenia )
Patients requiring blood transfusion due to anemia
Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies
Placenta previa or placental abruption
Previous major obstetric haemorrhage (>1000ml)in previous deliveries
Known fibroid or adenomyosis
Severe preeclampsia
Uterine anomalies
Women who received anticoagulant therapy
Facility Information:
Facility Name
Assiut Faculty of Medicine
City
Assiut
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage
We'll reach out to this number within 24 hrs